Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring

Kiki van Bilsen; Daphne P. C. Vergouwen; Mirjam van Velthoven; Tom O. A. R. Missotten; Saskia M. Rombach; Menno C. van Zelm; Magdalena A. Berkowska; P. Martin van Hagen; Robert W. A. M. Kuijpers; Jan A. M. van Laar

doi:10.1080/09273948.2023.2229900

Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring

Kiki van Bilsen, Daphne P. C. Vergouwen, Mirjam van Velthoven, Tom O. A. R. Missotten, Saskia M. Rombach, Menno C. van Zelm, Magdalena A. Berkowska, P. Martin van Hagen, Robert W. A. M. Kuijpers, Jan A. M. van Laar

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

14 Downloads (Pure)

Abstract

Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis.

Original language	English
Pages (from-to)	1268-1273
Number of pages	6
Journal	Ocular immunology and inflammation
Volume	32
Issue number	7
DOIs	https://doi.org/10.1080/09273948.2023.2229900
Publication status	Published - 2024

Bibliographical note

Publisher Copyright:
© 2023 The Author(s). Published with license by Taylor & Francis Group, LLC.

Copyright:
Copyright 2023 Elsevier B.V., All rights reserved.

Access to Document

10.1080/09273948.2023.2229900Licence: CC BY-NC

98035476Final published version, 1.8 MBLicence: CC BY-NC

Handle.net

Persistent link

Cite this

Bilsen, K. V., Vergouwen, D. P. C., Velthoven, M. V., Missotten, T. O. A. R., Rombach, S. M., Zelm, M. C. V., Berkowska, M. A., Hagen, P. M. V., Kuijpers, R. W. A. M., & Laar, J. A. M. V. (2024). Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring. Ocular immunology and inflammation, 32(7), 1268-1273. https://doi.org/10.1080/09273948.2023.2229900

@article{a68ffadf91cd4a6cad344f15d2ad2c77,

title = "Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring",

abstract = "Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis.",

author = "Bilsen, {Kiki van} and Vergouwen, {Daphne P. C.} and Velthoven, {Mirjam van} and Missotten, {Tom O. A. R.} and Rombach, {Saskia M.} and Zelm, {Menno C. van} and Berkowska, {Magdalena A.} and Hagen, {P. Martin van} and Kuijpers, {Robert W. A. M.} and Laar, {Jan A. M. van}",

year = "2024",

doi = "10.1080/09273948.2023.2229900",

language = "English",

volume = "32",

pages = "1268--1273",

journal = "Ocular immunology and inflammation",

issn = "0927-3948",

publisher = "Taylor and Francis Group",

number = "7",

}

TY - JOUR

T1 - Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring

AU - Bilsen, Kiki van

AU - Vergouwen, Daphne P. C.

AU - Velthoven, Mirjam van

AU - Missotten, Tom O. A. R.

AU - Rombach, Saskia M.

AU - Zelm, Menno C. van

AU - Berkowska, Magdalena A.

AU - Hagen, P. Martin van

AU - Kuijpers, Robert W. A. M.

AU - Laar, Jan A. M. van

PY - 2024

Y1 - 2024

N2 - Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis.

AB - Purpose: We report the long-term effect of rituximab (RTX) in scleritis and determine the value of B-cell monitoring for the prediction of relapses. Methods: We retrospectively studied 10 patients with scleritis, who were treated with RTX. Clinical characteristics were collected, and blood B-cell counts were measured before the start of RTX, and at various time points after treatment. Results: Clinical activity of scleritis decreased after RTX treatment in all patients within a median time of 8 weeks (range 3–13), and all reached remission. The median follow-up was 101 months (range 9–138). Relapses occurred in 6 out of 10 patients. All relapses, where B-cell counts were measured (11 out of 19), were heralded by returning B cells. However, B cells also returned in patients with long-term remissions. Conclusions: RTX is a promising therapeutic option for scleritis. Recurrence of B cells after initial depletion does not always predict relapse of scleritis.

UR - http://www.scopus.com/inward/record.url?scp=85165162387&partnerID=8YFLogxK

U2 - 10.1080/09273948.2023.2229900

DO - 10.1080/09273948.2023.2229900

M3 - Article

SN - 0927-3948

VL - 32

SP - 1268

EP - 1273

JO - Ocular immunology and inflammation

JF - Ocular immunology and inflammation

IS - 7

ER -

Long-Term Follow-Up of Patients with Scleritis After Rituximab Treatment Including B Cell Monitoring

Abstract

Bibliographical note

Access to Document

Handle.net

Other files and links

Fingerprint

Cite this